Novo Nordisk launches $9B bid to acquire Metsera, outpacing Pfizer's earlier offer, in a fierce competition to dominate the lucrative obesity drug market.
Eli Lilly posts blowout Q3 results, raises 2025 outlook, and sees strong demand for its GLP-1 medicines.
Novo Nordisk launches $9B bid to acquire Metsera, outpacing Pfizer's earlier offer, in a fierce competition to dominate the lucrative obesity drug market.
Eli Lilly posts blowout Q3 results, raises 2025 outlook, and sees strong demand for its GLP-1 medicines.